keyword
MENU ▼
Read by QxMD icon Read
search

Hepatocellular cancer resection

keyword
https://www.readbyqxmd.com/read/29782618/liver-targeted-therapies-for-hepatocellular-carcinoma-prior-to-transplant-contemporary-management-strategies
#1
Mustafa Nazzal, Sameer Gadani, Abdullah Said, Mandy Rice, Obi Okoye, Ahmad Taha, Krista L Lentine
Hepatocellular carcinoma (HCC) is an aggressive neoplastic disease that has been rapidly increasing in incidence. It usually occurs in the background of liver disease, and cirrhosis. Definitive therapy requires surgical resection. However, in majority of cases surgical resection is not tolerated, especially in the presence of portal hypertension and cirrhosis. Orthotopic liver transplant (OLT) in well selected candidates has been accepted as a viable option. Due to a relative scarcity of donors compared to the number of listed recipients, long waiting times are anticipated...
April 2018: Glob Surg
https://www.readbyqxmd.com/read/29774107/clinical-outcome-of-hepatocellular-carcinoma-can-be-predicted-by-the-expression-of-hepatic-progenitor-cell-markers-and-serum-tumour-markers
#2
Satoshi Seino, Atsunori Tsuchiya, Yusuke Watanabe, Yuzo Kawata, Yuichi Kojima, Shunzo Ikarashi, Hiroyuki Yanai, Koji Nakamura, Daisuke Kumaki, Masaaki Hirano, Kazuhiro Funakoshi, Takashi Aono, Takeshi Sakai, Jun Sakata, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Toshifumi Wakai, Shuji Terai
The high heterogeneity of hepatocellular carcinomas (HCCs) complicates stratification of HCC patients for treatment. Therefore, it is necessary to establish a comprehensive panel of HCC biomarkers related to tumour behaviour and cancer prognosis. Resected HCCs from 251 patients were stained for hepatic progenitor cell (HPC) markers epithelial cell adhesion molecule (EpCAM), neural cell adhesion molecule (NCAM), delta-like 1 homolog (DLK1), and cytokeratin 19 (CK19). Staining patterns were analysed for their prognostic association with relapse-free survival and overall survival...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29766659/prognosis-of-patients-with-hepatocellular-carcinoma-treated-with-sorafenib-a-comparison-of-five-models-in-a-large-canadian-database
#3
Haider H Samawi, Hao-Wen Sim, Kelvin K Chan, Mohammad A Alghamdi, Richard M Lee-Ying, Jennifer J Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo-Joung Ko, Janine M Davies, Howard J Lim, Winson Y Cheung, Vincent C Tam
Several systems (tumor-node-metastasis [TNM], Barcelona Clinic Liver Cancer [BCLC], Okuda, Cancer of the Liver Italian Program [CLIP], and albumin-bilirubin grade [ALBI]) were developed to estimate the prognosis of patients with hepatocellular carcinoma (HCC) mostly prior to the prevalent use of sorafenib. We aimed to compare the prognostic and discriminatory power of these models in predicting survival for HCC patients treated with sorafenib and to identify independent prognostic factors for survival in this population...
May 15, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29765517/targeting-the-mevalonate-pathway-is-a-novel-therapeutic-approach-to-inhibit-oncogenic-foxm1-transcription-factor-in-human-hepatocellular-carcinoma
#4
Satoshi Ogura, Yuichi Yoshida, Tomohide Kurahashi, Mayumi Egawa, Kunimaro Furuta, Shinichi Kiso, Yoshihiro Kamada, Hayato Hikita, Hidetoshi Eguchi, Hisakazu Ogita, Yuichiro Doki, Masaki Mori, Tomohide Tatsumi, Tetsuo Takehara
Dysregulation of cell metabolism is a hallmark of cancer. The mevalonate pathway in lipid metabolism has been implicated as a potential target of cancer therapy for hepatocellular carcinoma (HCC). The role of the Forkhead Box M1 (FoxM1) transcription factor in HCC development has been well documented, however, its involvement in cancer metabolism of HCC has not been fully determined. Here, we hypothesized that FoxM1 is involved in the mevalonate pathway of cholesterol biosynthesis in HCC. Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29765250/genetic-variants-in-the-exon-region-of-versican-predict-survival-of-patients-with-resected-early-stage-hepatitis-b-virus-associated-hepatocellular-carcinoma
#5
Xiaoguang Liu, Chuangye Han, Xiwen Liao, Long Yu, Guangzhi Zhu, Hao Su, Wei Qin, Sicong Lu, Xinping Ye, Tao Peng
Background: The upregulated expression of versican (VCAN) promotes the proliferation, invasion, and metastasis of various types of human cancer cells, including hepatocellular carcinoma (HCC) cells. Patients and methods: In this study, genetic variants in the exon region of VCAN were genotyped by DNA sequencing. Prognostic values of VCAN exon single nucleotide polymorphisms (SNPs) were assessed by Kaplan-Meier with the log-rank test, and uni- and multivariate Cox proportional hazard regression model...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29760585/mir-93-5p-enhance-lacrimal-gland-adenoid-cystic-carcinoma-cell-tumorigenesis-by-targeting-brms1l
#6
Jie Hao, Xin Jin, Yan Shi, Hong Zhang
Background: Lacrimal adenoid cystic carcinoma (LACC) is one of the most common malignancies that affects lacrimal gland. MicroRNAs are known to play a crucial role as oncogenes or tumor suppressors. Specifically, miR-93 has been reported to play a crucial role in colorectal, breast, pancreatic, lung cancer and hepatocellular carcinoma. However, the role of miR-93 in LACC and the potential molecular mechanisms involved remain unknown. Therefore, we took the challenge to determine the involvement of miR-93 in the LACC by targeting BRMS1L...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29755771/preoperative-survival-calculator-for-resectable-hepatocellular-carcinoma
#7
Emmanuel Gabriel, Jin Kim, Katherine T Ostapoff, Kristopher Attwood, Sergei Kurenov, Boris Kuvshinoff, Steven N Hochwald, Steven J Nurkin
Background: Estimation of preoperative overall survival (OS) of hepatocellular carcinoma (HCC) may guide surgical decision-making. Methods: OS was analyzed using the National Cancer Data Base from 1998-2012. Patients with HCC who underwent wedge resection, lobectomy or extended lobectomy were selected. Patients who had metastatic disease or previous treatment prior to surgery were excluded. Data was randomly allocated to model building (nb =4,364) and validation cohorts (nv =1,091)...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29755690/prognostic-value-of-line-1-methylation-level-in-321-patients-with-primary-liver-cancer-including-hepatocellular-carcinoma-and-intrahepatic-cholangiocarcinoma
#8
Tatsunori Miyata, Yo-Ichi Yamashita, Yoshifumi Baba, Kazuto Harada, Takanobu Yamao, Naoki Umezaki, Masayo Tsukamoto, Yuki Kitano, Kensuke Yamamura, Kota Arima, Shigeki Nakagawa, Hirohisa Okabe, Katsunori Imai, Daisuke Hashimoto, Akira Chikamoto, Mototsugu Shimokawa, Hideo Baba
Background: The methylation level of long interspersed nucleotide element-1 (LINE-1) is a good surrogate marker of the global DNA methylation level. The relationship between LINE-1 methylation level and prognosis in primary liver cancer (PLC) patients remains unclear. Results: LINE-1 methylation levels were significantly lower in HCC and cHCC-CC tissues, but not in ICC tissues, than those in noncancerous liver parenchyma (HCC: p < 0.0001; cHCC-CC: p < 0.001; and ICC: p = 0...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29754978/risk-stratification-using-a-novel-liver-functional-reserve-score-of-combination-prothrombin-time-international-normalized-ratio-to-albumin-ratio-and-albumin-in-patients-with-hepatocellular-carcinoma
#9
Koichiro Haruki, Hiroaki Shiba, Nobuhiro Saito, Takashi Horiuchi, Yoshihiro Shirai, Yuki Fujiwara, Kenei Furukawa, Taro Sakamoto, Katsuhiko Yanaga
BACKGROUND: Liver function in patients with hepatocellular carcinoma is generally graded according to the Child-Pugh system; however, some variables in the Child-Pugh grade are subjective. We developed a novel, objective score called the prothrombin time-international normalized ratio to albumin ratio. The aim of this study was to evaluate the prognostic value of this new score in patients with hepatocellular carcinoma after hepatic resection. METHODS: The study comprised 199 patients who underwent elective hepatic resection for hepatocellular carcinoma between January 2003 and December 2014...
May 10, 2018: Surgery
https://www.readbyqxmd.com/read/29733835/mechanisms-of-mafg-dysregulation-in-cholestatic-liver-injury-and-development-of-liver-cancer
#10
Ting Liu, Heping Yang, Wei Fan, Jian Tu, Tony W H Li, Jiaohong Wang, Hong Shen, JinWon Yang, Ting Xiong, Justin Steggerda, Zhenqiu Liu, Mazen Noureddin, Stephanie S Maldonado, Alagappan Annamalai, Ekihiro Seki, José M Mato, Shelly C Lu
BACKGROUND & AIMS: MAF bZIP transcription factor G (MAFG) is activated by the farnesoid X receptor (FXR) to repress bile acid synthesis. However, expression of MAFG increases during cholestatic liver injury in mice and in cholangiocarcinomas. MAFG interacts directly with methionine adenosyltransferase 1A (MAT1A) and other transcription factors at the E-box element to repress transcription. We studied mechanisms of MAFG upregulation in cholestatic tissues and the pathways by which S-adenosylmethionine (SAMe) and ursodeoxycholic acid (UDCA) prevent the increase in MAFG expression...
May 4, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29730905/assessment-of-the-surveillance-interval-at-1-year-after-curative-treatment-in-hepatocellular-carcinoma-risk-stratification
#11
Minjong Lee, Young Chang, Sohee Oh, Young Youn Cho, Dhong-Eun Jung, Hong Hyun Kim, Joon Yeul Nam, Hyeki Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Nam-Joon Yi, Kwang-Woong Lee, Dong Ho Lee, Jeong Min Lee, Jung-Hwan Yoon, Kyung-Suk Suh, Yoonjun Kim
Background/Aims: Guidelines recommend surveillance for hepatocellular carcinoma (HCC) recurrence at 3-month intervals during the first year after curative treatment and 6-month intervals thereafter in all patients. This strategy does not reflect individual risk of recurrence. We aimed to stratify risk of recurrence to optimize surveillance intervals during the first year after treatment. Methods: We retrospectively analyzed 1,316 HCC patients treated with resection/radiofrequency ablation at Barcelona Clinic Liver Cancer stage 0/A...
May 4, 2018: Gut and Liver
https://www.readbyqxmd.com/read/29729258/compliance-with-hepatocellular-carcinoma-surveillance-guidelines-associated-with-increased-lead-time-adjusted-survival-of-patients-with-compensated-viral-cirrhosis
#12
Charlotte Costentin, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Ghassan Riachi, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Eric Nguyen-Khac, Brigitte Bernard-Chabert, David Zucman, Vincent Di Martino, Angela Sutton, Eric Letouzé, Sandrine Imbeaud, Jessica Zucman-Rossi, Etienne Audureau, Françoise Roudot-Thoraval, Pierre Nahon
BACKGROUND AND AIMS: Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus (HCV)- or HBV-associated compensated cirrhosis who developed HCC. METHODS: We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France...
May 2, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29719937/a-novel-rna-sequencing-based-mirna-signature-predicts-with-recurrence-and-outcome-of-hepatocellular-carcinoma
#13
Bai Fumao, Huaibin Zhou, Mengni Ma, Chen Guan, Jianxin Lyu, Qing H Meng
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the second leading cause of cancer-related deaths worldwide. Given that the rate of HCC recurrence 5 years after liver resection is as high as 70%, patient with HCC typically have a poor outcome. A biomarker or set of biomarkers that could predict disease recurrence would have a substantial clinical impact, allowing earlier detection of recurrence and more effective treatment. With the aim of identifying a new microRNA (miRNA) signature associated with HCC recurrence, we analyzed data on 306 HCC patients for whom both miRNA expression profiles and complete clinical information were available from The Cancer Genome Atlas (TCGA) database...
May 2, 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29709236/radiofrequency-ablation-versus-surgical-resection-for-multiple-hccs-meeting-the-milan-criteria-propensity-score-analyses-of-10-year-therapeutic-outcomes
#14
J H Min, T W Kang, D I Cha, K D Song, M W Lee, H Rhim, D H Sinn, J M Kim, I Sohn
AIM: To assess the long-term therapeutic outcomes of radiofrequency ablation (RFA) versus surgical resection (SR) as a first-line treatment for patients meeting the Milan criteria with multiple hepatocellular carcinomas (HCCs). MATERIALS AND METHODS: This retrospective study was approved by the institutional review board and the requirement for informed consent was waived. Between January 2004 and December 2009, among 3,441 patients with treatment-naive HCCs, 88 patients meeting the Milan criteria with multiple HCCs (Barcelona Clinic Liver Cancer [BCLC] A stage) who underwent either RFA (n=62) or SR (n=26) were included...
April 27, 2018: Clinical Radiology
https://www.readbyqxmd.com/read/29692186/outcome-of-indeterminate-liver-lesions-on-computed-tomography-in-patients-with-colorectal-cancer
#15
E Mohamed, A Adiamah, W K Dunn, Y Higashi, I C Cameron, D Gomez
Introduction The aim of this study was to determinate the outcome of indeterminate liver lesions on computed tomography (CT) in patients with a background history of colorectal cancer (CRC) and to identify clinicopathological variables associated with malignancy in these lesions. A secondary aim was to devise a management algorithm for such patients. Methods Patients referred to our institution with indeterminate liver lesions on CT with a background history of CRC between January 2012 and December 2014 were included in the study...
April 25, 2018: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/29663340/molecular-signatures-in-hepatocellular-carcinoma-a-step-toward-rationally-designed-cancer-therapy
#16
REVIEW
Derek J Erstad, Bryan C Fuchs, Kenneth K Tanabe
Molecular characterization of hepatocellular carcinoma (HCC) has greatly improved our understanding of disease pathogenesis. Mutational analysis, RNA and microRNA expression profiling, and epigenetic characterization have revealed common aberrations in oncogenes and tumor suppressors that correlate with disease biology and serve as a guide for the rational design of targeted therapies. These approaches have also led to the discovery of novel targets, including mutations in isocitrate dehydrogenase and chromatin remodeling enzymes...
April 17, 2018: Cancer
https://www.readbyqxmd.com/read/29662832/hong-kong-consensus-statements-for-the-management-of-unresectable-hepatocellular-carcinoma
#17
Tom Tan-To Cheung, Philip Chong-Hei Kwok, Stephen Chan, Chin-Cheung Cheung, Ann-Shing Lee, Victor Lee, Hoi-Ching Cheng, Nam-Hung Chia, Charing C N Chong, Tak-Wing Lai, Ada L Y Law, Mai-Yee Luk, Chi Chung Tong, Thomas C C Yau
Background: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. Summary: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662831/the-asia-pacific-consensus-statement-on-laparoscopic-liver-resection-for-hepatocellular-carcinoma-a-report-from-the-7th-asia-pacific-primary-liver-cancer-expert-meeting-held-in-hong-kong
#18
Tan To Cheung, Ho-Seong Han, Wong Hoi She, Kuo-Hsin Chen, Pierce K H Chow, Boon Koon Yoong, Kit Fai Lee, Shoji Kubo, Chung Ngai Tang, Go Wakabayashi
Background: Laparoscopic liver resection has been gaining momentum, and it has become an accepted practice after the two international consensus conferences where experts worked up guidelines to standardize this approach and improve its safety. However, most laparoscopic hepatectomies were performed in patients with liver metastases. The concurrent presence of liver cirrhosis with hepatocellular carcinoma (HCC) poses a great challenge to clinicians trying to establish a routine use of laparoscopic liver resection for HCC...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29609485/treatment-for-occult-hepatocellular-carcinoma-does-it-offer-survival-advantages-over-symptom-driven-treatment
#19
Kwang Min Kim, Jiyu Kim, Dong Hyun Sinn, Hye Seung Kim, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
OBJECTIVE: In order to claim a benefit of screen-based diagnosis for asymptomatic individuals, treatment of occult disease needs to offer survival advantages compared to the treatment of symptomatic disease, yet information on this issue is scarce with regard to hepatocellular carcinoma (HCC) screening. METHODS: A total of 3353 treatment-naïve, consecutive, newly diagnosed HCC patients [age: 57.9 ± 10.3, male: 2,689 (80.2%), hepatitis B virus: 2555 (76.2%)], diagnosed between 2010 and 2013 were analyzed...
April 3, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29608544/treatment-optimization-for-hepatocellular-carcinoma-in-elderly-patients-in-a-japanese-nationwide-cohort
#20
Masaki Kaibori, Kengo Yoshii, Kiyoshi Hasegawa, Asao Ogawa, Shoji Kubo, Ryosuke Tateishi, Namiki Izumi, Masumi Kadoya, Masatoshi Kudo, Takashi Kumada, Michiie Sakamoto, Osamu Nakashima, Yutaka Matsuyama, Tadatoshi Takayama, Norihiro Kokudo
OBJECTIVE: We reviewed nationwide follow-up data to determine outcomes of different treatments for early-stage hepatocellular carcinoma (HCC) in elderly patients. SUMMARY BACKGROUND DATA: Outcomes of early-stage HCC treatments in elderly patients have not been prospectively compared. METHODS: We included 6490 HCC patients, aged ≥75 years at treatment, who underwent curative hepatic resection (HR, n = 2020), radiofrequency ablation (RFA, n = 1888), microwave ablation (MWA, n = 193), or transcatheter arterial chemoembolization (TACE, n = 2389), and compared their characteristics and survival...
March 30, 2018: Annals of Surgery
keyword
keyword
102251
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"